Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idec, GSK, Corixa Discussing Licensing Of Radioimmunotherapy Patents

Executive Summary

Idec is considering licensing patents from Corixa that may cover its radioimmunotherapy Zevalin.

You may also be interested in...



Corixa Bexxar patents ruled invalid

San Diego federal court grants Idec motion for summary judgment Oct. 10, declaring four Bexxar (tositumomab) patents (Nos. 5,595,721; 6,015,542; 6,090,365; 6,287,537) invalid based on inequitable conduct of the inventors in not disclosing highly material prior art before the Patent & Trademark Office. "The manner in which [the work] was brought before the PTO cannot be described as anything short of misleading and inaccurate," the ruling states. Corixa and Bexxar marketing partner GSK originally sought to enjoin Idec from infringing the '721, '542, and '365 patents (1"The Pink Sheet" Sept. 24, 2001, p. 29). Corixa plans to appeal the ruling...

Corixa Bexxar patents ruled invalid

San Diego federal court grants Idec motion for summary judgment Oct. 10, declaring four Bexxar (tositumomab) patents (Nos. 5,595,721; 6,015,542; 6,090,365; 6,287,537) invalid based on inequitable conduct of the inventors in not disclosing highly material prior art before the Patent & Trademark Office. "The manner in which [the work] was brought before the PTO cannot be described as anything short of misleading and inaccurate," the ruling states. Corixa and Bexxar marketing partner GSK originally sought to enjoin Idec from infringing the '721, '542, and '365 patents (1"The Pink Sheet" Sept. 24, 2001, p. 29). Corixa plans to appeal the ruling...

Idec Zevalin May Need Central Monitoring Of Bio-Images, FDA Cmte. Suggests

Idec should establish a centralized monitoring program to assess Zevalin biodistribution images, FDA Oncologic Drugs Advisory Committee Chair Stacy Nerenstone, MD, Helen & Harry Gray Cancer Center, suggested during the Sept. 11 review of the radioimmunotherapy.

Related Content

UsernamePublicRestriction

Register

PS038536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel